Kimia Biosciences BSE:530313 Lagerbericht Finanzdaten des Unternehmens
Kimia Biosciences Limited
BSE:530313 Lagerbericht
Marktkapitalisierung: ₹2.2b
530313 Aktienübersicht Kimia Biosciences Limited produziert und vertreibt pharmazeutische Wirkstoffe in Indien.
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Kimia Biosciences Limited Wettbewerber Preisentwicklung & Leistung
Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Kimia Biosciences Historische Aktienkurse Aktueller Aktienkurs ₹47.32 52-Wochen-Hoch ₹58.40 52-Wochen-Tief ₹33.20 Beta 0.93 11 Monat Veränderung -5.38% 3 Monate Veränderung -7.20% 1 Jahr Veränderung 25.52% 33 Jahre Veränderung 19.80% 5 Jahre Veränderung 84.48% Veränderung seit IPO 408.82%
Aktuelle Nachrichten und Updates
First quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.57 loss in 1Q 2024) Aug 21
New minor risk - Share price stability Aug 07
Full year 2024 earnings released: ₹1.12 loss per share (vs ₹1.98 loss in FY 2023) Jun 15
Kimia Biosciences Limited to Report Q4, 2024 Results on May 30, 2024 May 23
Insufficient new directors Apr 11
New minor risk - Share price stability Mar 05 Weitere Updates anzeigen
First quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.57 loss in 1Q 2024) Aug 21
New minor risk - Share price stability Aug 07
Full year 2024 earnings released: ₹1.12 loss per share (vs ₹1.98 loss in FY 2023) Jun 15
Kimia Biosciences Limited to Report Q4, 2024 Results on May 30, 2024 May 23
Insufficient new directors Apr 11
New minor risk - Share price stability Mar 05
Third quarter 2024 earnings released: ₹0.41 loss per share (vs ₹0.98 loss in 3Q 2023) Feb 17
Kimia Biosciences Limited to Report Q3, 2024 Results on Feb 14, 2024 Feb 07
Second quarter 2024 earnings released: ₹0.52 loss per share (vs ₹0.18 loss in 2Q 2023) Nov 14 Kimia Biosciences Limited to Report Q4, 2025 Results on May 30, 2025
Kimia Biosciences Limited Announces Chief Financial Officer Changes Sep 08
Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023 Sep 02
Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director ) Aug 29
First quarter 2024 earnings released: ₹0.57 loss per share (vs ₹0.23 profit in 1Q 2023) Aug 16
Full year 2023 earnings released: ₹1.98 loss per share (vs ₹0.78 loss in FY 2022) Jun 04
Insufficient new directors Nov 16
Kimia Biosciences Limited to Report First Half, 2023 Results on Nov 14, 2022 Nov 05 Kimia Biosciences Limited to Report Q4, 2023 Results on Apr 12, 2023
Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022 Sep 07
Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022 Sep 06
First quarter 2023 earnings released: EPS: ₹0.23 (vs ₹0.07 in 1Q 2022) Aug 18
Full year 2022 earnings released: ₹0.78 loss per share (vs ₹1.08 profit in FY 2021) Jun 05
Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer May 31
Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer May 24
Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials May 19
Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary May 17
Insufficient new directors Apr 27
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 17
Kimia Biosciences Limited to Report Q3, 2022 Results on Feb 14, 2022 Feb 06
Insufficient new directors Jan 02
Company Secretary & Compliance Officer Abhishek Pandey has left the company Nov 30
First quarter 2022 earnings released: EPS ₹0.07 (vs ₹0.43 in 1Q 2021) Aug 18
Full year 2021 earnings released: EPS ₹1.08 (vs ₹0.33 in FY 2020) Jun 24
Investor sentiment improved over the past week Apr 26
Kimia Biosciences Limited Bags Permission to Manufacture Bilastine API New Active Pharmaceutical Ingredient for Sale or for Distribution Mar 17
Kimia Biosciences Limited Receives Permission to Manufacture New Active Pharmaceutical Ingredient for Sale or for Distribution Feb 23
New 90-day low: ₹40.75 Feb 17
Third quarter 2021 earnings released: EPS ₹0.09 (vs ₹0.03 in 3Q 2020) Feb 14
Kimia Biosciences Limited to Report Q3, 2021 Results on Feb 11, 2021 Feb 02
Investor sentiment improved over the past week Jan 04
New 90-day high: ₹50.80 Jan 01
New 90-day high: ₹44.95 Dec 09
Market bids up stock over the past week Nov 19
Market bids up stock over the past week Nov 10
Kimia Biosciences Limited to Report Q2, 2021 Results on Nov 05, 2020 Oct 27
Kimia Biosciences Limited Approves Appointment of Vipul Goel as Non Executive, Non Independent Director Oct 01
First quarter earnings released Aug 19
New 90-day high - ₹33.80 Aug 11
Kimia Biosciences Limited to Report Q1, 2021 Results on Aug 18, 2020 Aug 08 Aktionärsrenditen 530313 IN Pharmaceuticals IN Markt 7D -3.9% -1.7% 0.1% 1Y 25.5% 48.6% 33.4%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 530313 unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 48.6% erzielte.
Rendite vs. Markt: 530313 hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 33.4 erzielte.
Preisvolatilität Is 530313's price volatile compared to industry and market? 530313 volatility 530313 Average Weekly Movement 5.0% Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.2% 10% least volatile stocks in IN Market 3.9%
Stabiler Aktienkurs: 530313 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: 530313Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Kimia Biosciences Limited produziert und vertreibt pharmazeutische Wirkstoffe in Indien. Es exportiert seine Produkte. Das Unternehmen war früher als Laurel Organics Ltd bekannt und änderte im Januar 2019 seinen Namen in Kimia Biosciences Limited.
Mehr anzeigen Kimia Biosciences Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Kimia Biosciences im Vergleich zum Marktanteil des Unternehmens? 530313 grundlegende Statistiken Marktanteil ₹2.24b Gewinn(TTM ) -₹11.61m Umsatz(TTM ) ₹1.03b
2.2x Kurs-Umsatz-Verhältnis
-192.8x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 530313 Gewinn- und Verlustrechnung (TTM ) Einnahmen ₹1.03b Kosten der Einnahmen ₹695.89m Bruttogewinn ₹334.56m Sonstige Ausgaben ₹346.18m Umsatz -₹11.61m
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
Nov 14, 2024
Gewinn per Aktie (EPS) -0.25 Bruttomarge 32.47% Nettogewinnspanne -1.13% Schulden/Eigenkapital-Verhältnis 14,959.0%
Wie hat sich 530313 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
